Advertisement

Advances in Therapy

, Volume 27, Issue 7, pp 476–482 | Cite as

Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?

  • Vanessa V. MercadoEmail author
  • Ioana Cristea
  • Noorjahan Ali
  • ChauChau Pham
  • Elizabeth Buescher
  • Jean Yang
  • Joie Fisher
  • Hima Maramreddy
  • Johanna Calo
  • Sonya Strassberg
  • Lance A. Parton
Original Research

Abstract

Introduction

The objective of this study was to compare the pulmonary inflammatory response of premature infants with respiratory distress following instillation of one of two commonly available surfactant preparations.

Methods

This was a prospective, randomized investigation of preterm infants who were less than 30 weeks of gestational age, weighed less than 1 kg at birth, and who qualified to receive surfactant. Infants with multiple congenital anomalies or whose mothers were taking anti-inflammatory medications were ineligible. Tracheal aspirates (TAs) were collected on days 1, 3, 5, and 7 and airway cytokines from TAs were assayed for interleukin (IL)-8 and IL-6.

Results

Infants were evenly matched by gestation (26±2 days and 26±1 days [mean±SD], Surfactant A and B, respectively) and birth weight (730±141 g and 732±167 g). TA cytokine levels were not different between or within groups. Ventilator requirements and clinical outcomes were similar between the two groups.

Conclusion

The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation.

Keywords

bronchopulmonary dysplasia cytokine interleukin 6 cytokine interleukin 8 natural surfactants respiratory distress syndrome tracheal aspirate cytokine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ainsworth SB, Beresford MW, Milligan DW, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks’ gestation: a randomised trial. Lancet. 2000;35:1387–1392.CrossRefGoogle Scholar
  2. 2.
    Hudak ML, Farrell EE, Rosenberg AA, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr. 1996;128:396–406.CrossRefPubMedGoogle Scholar
  3. 3.
    Hudak ML, Martin DJ, Egan EA, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics. 1997;100:39–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Kukkonen AK, Vertanen M, Järvenpää AL, Pokela ML, Ikonen S, Fellman V.. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr. 2000;89:510–512.CrossRefGoogle Scholar
  5. 5.
    Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child. 1995;72:F8–F13.Google Scholar
  6. 6.
    Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomised, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004;21:109–119.CrossRefPubMedGoogle Scholar
  7. 7.
    Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol. 1999;24:331–336.CrossRefGoogle Scholar
  8. 8.
    Jonsson B, Tullus K, Brauner A, Lu Y, Noack G. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;77:F198–F201.CrossRefPubMedGoogle Scholar
  9. 9.
    Kakkera DK, Siddiq MM, Parton LA. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biol Neonate. 2005;87:82–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Speer CP, Gotze B, Curstedt T, Robertson B. Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf). Pediatr Res. 1991;30:69–74.PubMedGoogle Scholar
  11. 11.
    Baur FM, Brenner B, Goetze-Speer B, Neu S, Speer CP. Natural porcine surfactant (Curosurf) downregulates mRNA of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha type II receptor in lipopolysaccharide-stimulated monocytes. Pediatr Res. 1998;44:32–36.CrossRefPubMedGoogle Scholar
  12. 12.
    Halliday HL, Tarnow-Mordi W, Corcoran JD, Patterson CC. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child. 1993;69:276–280.CrossRefPubMedGoogle Scholar
  13. 13.
    Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991;88:19–28.PubMedGoogle Scholar
  14. 14.
    Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–1729.PubMedGoogle Scholar
  15. 15.
    Ehrenkranz RA, Walsh MC, Vohr BR, et al. National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353–1360.CrossRefPubMedGoogle Scholar
  16. 16.
    Talati AJ, Crouse DT, English BK, Newman C, Harrison L, Meals E. Immunomodulation by exogenous surfactant: effect on TNF-alpha secretion and luminol-enhanced chemiluminescence activity by murine macrophages stimulated with group B streptococci. Microbes Infect. 2001;3:267–273.CrossRefPubMedGoogle Scholar
  17. 17.
    Strunk T, Temming P, Gembruch U, Reiss I, Bucsky P, Schultz C. Differential maturation of the innate immune response in human fetuses. Pediatr Res. 2004;56:219–226.CrossRefPubMedGoogle Scholar
  18. 18.
    Schultz C, Temming P, Bucsky P, Göpel W, Strunk T, Härtel C. Immature anti-inflammatory response in neonates. Clin Exp Immunol. 2004;135:130–136.CrossRefPubMedGoogle Scholar
  19. 19.
    Ripalda MJ, Rudolph N, Wong SL. Developmental patterns of antioxidant defense mechanisms in human erythrocytes. Pediatr Res. 1989;26:366–369.CrossRefPubMedGoogle Scholar
  20. 20.
    Dani C, Cecchi A, Bertini G. Role of oxidative stress as physiopathologic factor in the preterm infant. Minerva Pediatr. 2004;56:381–394.PubMedGoogle Scholar
  21. 21.
    Rozycki HJ, Comber PG, Huff TF. Cytokines and oxygen radicals after hyperoxia in preterm and term alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2002;282:1222–1228.Google Scholar
  22. 22.
    Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005;94:779–784.CrossRefPubMedGoogle Scholar
  23. 23.
    Strassberg SS, Cristea IA, Qian D, Parton LA. Single nucleotide polymorphisms of tumor necrosis factor-alpha and the susceptibility to bronchopulmonary dysplasia. Pediatr Pulmonol. 2007;42:29–36.CrossRefPubMedGoogle Scholar
  24. 24.
    Parton, LA, Strassberg SS, Qian D, Galvin-Parton PA, Cristea IA. The genetic basis for bronchopulmonary dysplasia. Front Biosci. 2006;11:1854–1860.CrossRefPubMedGoogle Scholar
  25. 25.
    Bhandari V, Gruen JR. The genetics of bronchopulmonary dysplasia. Semin Perinatol. 2006;30:185–191.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Vanessa V. Mercado
    • 1
    Email author
  • Ioana Cristea
    • 1
  • Noorjahan Ali
    • 1
  • ChauChau Pham
    • 1
  • Elizabeth Buescher
    • 1
  • Jean Yang
    • 1
  • Joie Fisher
    • 2
  • Hima Maramreddy
    • 1
  • Johanna Calo
    • 1
  • Sonya Strassberg
    • 1
  • Lance A. Parton
    • 1
  1. 1.Maria Fareri Children’s HospitalNew York Medical CollegeValhallaUSA
  2. 2.Children’s Hospital of New Jersey-Newark Beth Israel Medical CenterNewarkUSA

Personalised recommendations